Chief Executive Jim Conroy, in the seat since February 2025, has pushed the merchant organization into better and more popular brands without systematically raising price points, and says closeout opportunities are very strong, with mainstream retail's softness freeing up canc...
Read Article ›What kills single-asset biotechs is not usually the science; it is being forced to sell equity into bad news and AbCellera has removed that mechanism for the window in question.
Read Article ›The standing critique of Rocket Lab is simple: elite growth, elite vision, no profits, and a valuation that requires everything to go right. The Iridium acquisition is the most direct possible response to that critique, because Iridium is the thing Rocket Lab has never had—a c...
Read Article ›The company is printing record revenue, expanding swaps share across every major currency, growing international past 40% of the mix, and converting more than $1 billion to free cash flow — yet the stock sits near a 52-week low because investors have fixated on a fee-per-milli...
Read Article ›